
Himed, a biomaterials manufacturer and developer of surface enhancements for medical implants in the dental and orthopedic markets, announced a strategic leadership transition effective January 1, 2024.
Craig Rosenblum is appointed as the new President of Himed. He succeeds Ed Garofalo, who will transition into the advisory position of President Emeritus.
Rosenblum’s guidance has helped propel Himed to achieve remarkable milestones and solidified its position as an industry leader in biomaterials for medical devices, leading to his promotion. Having joined the company in 2015, he seamlessly transitioned through three distinct roles, culminating in his current position as Vice President and General Manager.
After more than three decades at the helm, Himed’s esteemed co-founder Ed Garofalo will continue providing invaluable support to the company as it enters its next phase of growth. This transition reflects Garofalo’s dedication to Himed’s ongoing success. Says Garofalo, “It’s very gratifying to see innovations we made decades ago positively impacting the efficacy of various medical devices around the world. In the early 1990s, calcium phosphates like hydroxyapatite were not being widely used, but now they factor significantly into all kinds of implants. I’m grateful that I can continue to contribute meaningfully to Himed’s future development, even as I pass along the responsibilities of daily leadership.”
Himed’s ongoing success is a reflection of a customer-centric culture that Ed Garofalo championed from the beginning. Rosenblum states, “Ed has always focused the company on meeting specific customer needs. To this day, we listen deeply to the biomaterial problems our customers face and are committed to finding tailored materials solutions to support their goals.”
Rosenblum sees 2024 as a year to focus on Himed’s newly formed research partnerships and enhance analytical service offerings through expanded on-site testing and prototyping capabilities. “As we embrace the possibilities of technology and innovation, we recognize the pivotal role that biomaterials play in shaping healthcare. Himed is committed to producing high-quality solutions that help the body heal,” he says. “I intend to foster an environment that encourages groundbreaking research and collaboration. Ed has proven that if we stay focused on the needs of our customers, they will stay committed to Himed for decades.”
Source: Himed
JAV
Julie A. Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.